Board of Directors
Trained as a Registered Nurse in the UK, on arrival in Australia she became a Director of Nursing and Chief Executive Officer of two private hospitals. Following this she established an Australian and International consulting business which was sold to Healthsouth a large US Healthcare company. After this she became the Co-founder of Vision Group an Opthalmic Doctor equity consolidation model which was successfully listed on the ASX.
Jayne joined a number of private Healthcare Boards involved with specialist consolidation including Cardiology, Orthopaedics, and Women’s Health she continued to work with Private Equity firms on local and International Healthcare transactions. Jayne, together with Ron Phillips was a co-owner of Sydney Breast Clinic and a co-founder of BCAL Diagnostics. Current Board positions are Critical Group – Heatley’s Industrial Supplies, The Woolcock Research Institute, and The Hareda Foundation established to invest in Women’s Health Initiatives.
The Hon Ron Philips (AO)
Biospecimen and Clinical Research
Following 15 years in the NSW Parliament which included serving as Minister for Health and Deputy Leader of the Opposition, Ron developed a successful consulting business in the Health and Aged Care Industry.
His business interests included co-owner and Managing Director of Sydney Breast Clinic which he sold to Healthscope. He currently serves as Chair of the Sydney Local Health District and as Director on Westmead IVF.
Independent Non-Executive Director
Jonathan is a globally experienced independent director with over 30 years commercial, corporate, governance and legal and transactional expertise. Jonathan is currently non-executive independent chairman of ASX listed Global Value Fund Ltd Future Generation Investment Company Ltd , Antipodes Global Investment Company Ltd and Plato Income Maximizer Limited . He is a non-executive director of ASX listed Kore Potash Limited and holds private company directorships in the commercial and not-for-profit sectors.
Jonathan was a principal of Sydney, Australia based structured finance group Meridian International Capital Limited for over 20 years, Prior to that, Jonathan was a partner with law firm Herbert Smith Freehills. Jonathan currently has a New South Wales Law Society Practicing Certificate and is a Fellow of the Australian Institute of Company Directors.
Independent Non-Executive Director
Dr. Sleigh has over 30 years of experience as a senior executive and non-executive director in Australia’s biotechnology sector. She was, from its foundation, Chief Executive Officer and Managing Director of EvoGenix Limited, a biotech startup company that expanded internationally and listed on the ASX before acquisition by a larger company.
She was formerly Dean of the Faculty of Life Sciences, University of NSW; Director of Research & Development at Australian biotech Peptech Ltd and a research scientist and senior manager with CSIRO. She has held non-executive director positions with Mimetica Pty Ltd and Adalta Ltd as well as with ASX listed companies Clover Corporation, and Tyrian Diagnostics Ltd.
Other director roles have been with government and not-for-profit organisations, including the Rural Industries Research and Development Corporation and Relationships Australia
Mark Burrows AO
Independent Non-Executive Director
Mark Burrows AO joined the BCAL Board on a pro-bono basis, as he is an advocate for early diagnosis of breast cancer and other cancers. He has enjoyed a long and distinguished career in investment banking both in Australia and the UK. Mark co-founded Baring Brothers Burrows & Co in Australia in the early 80s. In 1999 he was appointed the Managing Director/ Deputy Chairman of ING Barings in London. During his extensive investment banking career, Mark has been the principal financial advisor to some of the most significant and transformative corporate and government transactions in Australia. Mark has served as a non-executive director on several Australasian and UK public companies including Chairman and Deputy Chair of Brambles, Fairfax Media and Telstra.
Chief Executive Officer
Dr Hurrell has developed and successfully commercialized multiple products and services in life sciences and diagnostics over a career in the industry spanning more than 35 years. He has developed and managed start-up and early-stage companies including successful life science companies based on university developed technologies. Most notably Dr Hurrell spent almost 7 years in managerial and executive roles with NYSE-listed, Fortune 500 clinical laboratory company Quest Diagnostics. Within Quest’s subsidiary Focus Diagnostics, he led the development and launch of more than 70 molecular diagnostics tests and successfully gained 510(k) approvals for 6 products. He also served as VP of Business Development at Quest Diagnostics.
Dr Amani Batarseh, PhD
Chief Scientific Officer
Dr Amani Batarseh is the company’s Chief Scientist. She graduated magna cum laude from La Roche College in Pennsylvania where she had a Pacem in Terris scholarship for academic excellence. Later, she received a fellowship to purse her PhD at Georgetown University, Washington, DC in Biochemistry and Molecular & Cellular Biology. Amani completed post doctoral studies at Harvard University, McGill University and Wollongong University. During her time in Canada, Amani managed and established two mass spectrometry laboratories being at the Research Institute of McGill University Hospital and The Glen Hospital in Montreal, respectively. Her versatile profile of expertise combines molecular biology with lipidomics and mass spectrometry to answer biological questions.
Dr Kim Ekroos, PhD
Lipidomics and Mass Spectrometry
Kim Ekroos is the founder and CEO of Lipidomics Consulting Ltd., a consulting business providing unique services for customers globally in the field of Lipidomics. He received his Ph.D. degree in biology from the Technical University in Dresden, Germany, in 2003. His expertise includes high-throughput technologies for the precise assessment of lipidomes enabled by advanced mass spectrometry, automation, and software tools towards discovery of biological architectures and of diagnostic biomarkers for clinical purpose.
Kim is a globally experienced independent consultant for Lipidomics with over 20 years academics, healthcare and industry expertise. He has a number of patents for biomarker discovery, numerous peer-reviewed publications and an editor of a widely read Lipidomics book. He is the current president of the newly founded International Lipidomics Society (ILS) to which the Lipidomics Standards.
A/Prof Craig Gedye
BSc(Hons), MBChB, FRACP, PhD
Biospecimen and Clinical Research
Craig Gedye is a medical oncologist and cancer researcher. He works for people with melanoma, brain, prostate, bladder and kidney cancers at the Calvary Mater Newcastle and is the Clinical Research Director at the NSW Health Statewide Biobank.
His research in the School of Medicine and Public Health at the University of Newcastle/Hunter Medical Research Institute focuses on complexity and heterogeneity in cancer – "why are cancers different between different people; why are cancers cells different to each other; what does this mean for each person’s treatment?"
Craig is leading several national cancer clinical trials for the ANZUP and COGNO trials groups, and is a member of the Mark Hughes Scientific Advisory Committee, HNEHLD Clinical Trials Ethics Subcommittee and ANZUP Cancer. He has been awarded numerous scholarships, fellowships, grants, investigator-initiated clinical trials, publications, conference presentations and prizes.
Dr. Sanjay Warrier (Associate Prof.)BSc (Med) MBBS FRACS MS
Consultant Breast Oncology and Oncoplastic Surgeon
Consultant Breast Oncology and Oncoplastic Surgeon at Chris O’Brien Lifehouse, Royal Prince Alfred and Mater Hospitals. He is also a Visiting Medical Officer at BreastScreen NSW.
An Associate Professor of the University of Sydney with the Royal Prince Alfred Academic Institute. He is lead researcher at the Institute with goals of developing and creating a culture of academia within the Breast Department.
Won the Patron’s Prize at the Royal Prince Alfred Hospital for best scientific research. Sanjay has also published many papers and co-authored articles in peer reviewed journals and magazines. Sanjay is Chairman of Post-Fellowship Training for BreastSurgANZ, a role that involves training future breast surgeons in Australia and New Zealand.
Prof. Peter Meikle, PhD
Baker IDI Lipidomics Melbourne
Peter is an NHMRC Senior Research Fellow at the Baker Institute. He leads the Obesity and Diabetes Program and is Head of the Metabolomics laboratory. He is also Editor in Chief of the journal Metabolites and holds affiliate positions at the University of Melbourne, Monash University and the NHMRC Clinical Trials Centre, University of Sydney.
The Metabolomics laboratory uses state of the art tandem mass spectrometry to obtain metabolic profiles from cell and animal models in addition to clinically relevant human samples. This approach is providing an improved understanding of disease mechanisms leading to new biomarkers for improved diagnosis and risk assessment as well as new therapeutic strategies in the areas of obesity, diabetes and cardiovascular disease.
Dr. Mary Rickard OAM
MBBS, BSc(Med)(HonsII), DRACR, DDU, MPH, RANZCR
Dr Mary Rickard received a Member of the Order of Australia award in 2002, for service to medicine through the integration of population-based screening for early detection of breast cancer, and the development of education programs for health professionals.
She is also involved in consulting with numerous breast screening and diagnostic training programs across South East Asia, in particular Singapore, Indonesia, Malaysia, Thailand, Japan and most recently Mongolia.
Dr Desmond Li
Dr Desmond Li completed his PhD at The University of Sydney, exploring protein, metabolite and lipid markers for the development of type 2 diabetes by mass spectrometry. He conducted post doctoral studies at the Heart Research Institute, Australia, applying his mass spectrometry skills in the context of heart failure. Prior to his PhD, Desmond has worked in analytical labs gaining skills in routine testing, quality management and lab management. His interests are in applying mass spectrometry techniques to further understand human diseases.
Helen provides support to both the Chief Scientist and CEO. She has over 30 years’ experience in the clinical diagnostic field, starting at the ‘coal face’ in Public Hospital and Private Pathology laboratories to multinational commercial IVDD manufacturers and suppliers. Her expertise includes diagnostic techniques and methods, regulatory affairs, quality management systems, and technical marketing. Helen holds a B.App.Sc Biomedical Science from U.T.S.
Helen is passionate about healthcare and in particular the diagnostic pathology industry and the quality use of pathology to provide better long-term healthcare for all.
Cheka graduated from the University of Melbourne with a PhD in Plant Lipidomics. Her expertise and interests include developing untargeted and targeted liquid-chromatography-mass spectrometry based lipidomic workflows, and activity guided fractionation of bioactive compounds from plants and fungi for drug discovery.
Cheka is an avid reader who is always on the look out to apply new discoveries and state-of-the-art technologies to enhance her research practices. She loves to share her research findings and ideas through journal articles and conferences.
Cheka is an enthusiastic collaborator and enjoys partnering with scientists across academia and industry to advance the field of lipidomics, natural products chemistry and biomarker discovery.
Dr Mark David
Dr Mark David is the company’s research scientist and has over 15 years of experience in analytical chemistry in both industry and academia. He started his professional career as a hospital scientist in the forensic toxicology department at Forensic Analytical Science Services (FASS) in NSW, Australia, a position he held for nearly a decade.
His love of travelling subsequently took him to London, where he worked as a mass spectrometry researcher at the National Phenome Centre whilst he simultaneously undertook and completed his PhD in biochemistry at Imperial College London. Mark’s PhD focussed on developing analytical and statistical strategies/workflows to increase coverage of metabolites relating to xenobiotics from metabolomic datasets.
Kerry is the company’s Research Assistant. Kerry recently graduated with First Class Honours from the University of Sydney. He presented his Honours project at the 2019 ASCEPT-PAGANs conference in Queenstown NZ.
Kerry as a diverse range of professional interests including health, carcinogenesis, machine learning, programming and metabolomics.
Mr Paul Cohen B.AppSc (Biomedical)
Clinical Trial Coordinator
Paul has greater than 26 years’ experience in the diagnostics, biotechnology, medical device, and bio-pharmaceutical industry. His expertise spans clinical research, regulatory affairs, pharmacovigilance, training, quality management and process re-engineering for large pharmaceutical companies, biotech and medical device/IVD start-up ventures.
His clinical research therapeutic area expertise includes medical devices-CLASS I-III, IVDs, vaccines and biologicals, anti-infectives, transplantation, antidepressants, rheumatology, oncology, diabetes, respiratory and orthopaedics.
market/PV pre and post market obligations and risk management. He holds an ARCS Certified Fellowship in Clinical Research and is a member of ARCS, AIMS, ASM, RAPS and a Subject Matter Expert for the World Medical Device Organisation.
BCAL Other Key Members
Chief Financial Officer & Company Secretary
A Finance Director/Chief Financial Officer for a number of companies within the Jardine Matheson Group over a period of 16 years. Guy provided CFO consulting services to many large corporations and SMEs. CFO/Company Secretary for a number of Australian public companies including Evogenix Limited and is currently a Director of ASX-listed entities Metal Bank Limited and Hastings Technology Metals Ltd.
Company Secretary for Bioxyne Limited, Artemis Resources Limited and Truscreen Limited
Experience across Consumer Healthcare, FMCG and Startups specialising in brand management and digital marketing. Rebecca has worked on some of Australia's market leading Consumer Healthcare brands such as Panadol, Voltaren, Centrum and Sensodyne to drive brand growth and sales.
Corporate Finance Advisor
Charlie has 30 years of global capital raising and mergers and acquisitions experience. After a career holding senior positions at Baring Brothers, Macquarie Bank, Investec and EY, working in Australia, SE Asia, South Africa and the UK, he now runs an independent advisory boutique. Charlie has an M&A in Economics from Cambridge University, is a Fellow of the Institute of Chartered Accountants in England and Wales and is a Graduate of the Australian Institute of Company Directors.